The Asthma and Allergy Foundation of America (AAFA) conducted the My Life With Asthma survey to highlight the challenges people with asthma, especially severe asthma, face. We found that people with asthma have concerns beyond their physical health. Many deal with fear and worry.
Last year’s top Asthma Capital, Springfield, Massachusetts, is again the most challenging place in the U.S. to live with asthma. To get a better understanding of the asthma problem there, we talked with a local family, senator, allergist and city councilor.
Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.
In this essay, you’ll hear from Peter DeMarco of Boston, Massachusetts, who lost his wife, Laura Levis, to asthma. Boston ranks #8 on our 2019 Asthma Capitals report. It has such a high ranking because of a high number of people with asthma and asthma-related deaths.
On May 7, 2019, World Asthma Day, the Asthma and Allergy Foundation of America (AAFA) released its 2019 Asthma Capitals Report™. This report ranks the top 100 most challenging places in America to live with asthma.
Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. We also want to help people see beyond asthma and allergies. This year, we aim to do just that through our themes, “More Than Asthma” and “More Than Food Allergies.”
This year’s theme for World Allergy Week is The Global Problem of Food Allergy. To help us take action on food allergies, we are seeking 1,000 individuals to fill out a survey that may take 15-30 minutes (the length of the survey depends on your answers).
The Asthma and Allergy Foundation of America (AAFA) has released the 2019 Spring Allergy Capitals™ report to look at why some locations are more affected than others. Our report ranks the top 100 cities in the nation for spring allergies.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Alpha-gal syndrome (AGS), a food allergy commonly known as red meat allergy, may develop from ticks’ saliva itself, whether a tick has fed on another animal before biting a human or not. This news comes from a study presented for the first time at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology.
Controlled burns are often used to help reduce and contain wildfires, but it turns out which burn is occurring can actually have an effect on your health, according to research presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline (GSK) to bring you the latest research news quickly. [PRESS RELEASE] GSK Announces Availability of Authorized Generic ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder) GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be...
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. Learn more.